HER3-Targeted Therapies for EGFRm NSCLC: Key Evidence and Real-world Insights to Optimize Patient Care

Enhance your knowledge of HER3 overexpression in EGFR-mutated non-small-cell lung cancer and gain strategies for developing individualized treatment plans incorporating HER3-targeted therapies in patients with acquired resistance to EGFR tyrosine kinase inhibitors, through a series of text modules with accompanying downloadable slidesets and an expert-authored commentary.

Share

Program Content

Activities

HER3 EGFRm NSCLC Care
HER3-Targeted Therapies for EGFRm NSCLC: Emerging Therapies and Challenges in Treatment
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 09, 2024

Expires: October 08, 2025

Activities

NSCLC HER3 AE Management
Optimizing HER3-Targeted Therapy for NSCLC: Strategies for Early Detection and Management of Adverse Events 
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: June 05, 2025

Activities

NSCLC HER3 AE Management
Optimizing HER3-Targeted Therapy for NSCLC: Strategies for Early Detection and Management of Adverse Events
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: December 04, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.